Opportunities EIS Fund
3 Pancras Square, London, England, N1C 4AG, United Kingdom
Overview
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009, anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth. Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 9
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- Creavo Medical Technologies
Led · Equity · Jul 2017
Creavo Medical Technologies is a University of Leeds spin‑out and UK‑based med‑tech company that has developed a deployable diagnostic technology using magnetocardiography (MCG) to measure electromagnetic fluctuations caused by heart activity with extremely sensitive detectors. Its Vitalscan device can more accurately 'rule out' heart‑related problems at point of admission to emergency departments and is estimated to be able to save the NHS £200 million a year. Creavo's core technology has a range of potential applications beyond emergency detection, including helping to better understand and predict arrhythmias that can result in sudden cardiac death and supporting diagnostics in other organs. The company completed an oversubscribed £13.4 million fundraising that exceeded its funding target and was strongly supported by existing shareholders and new investors. Investors named in reports include Parkwalk Opportunities Fund (Parkwalk Advisors), IP Group plc, the University of Leeds and Puhua Capital Ltd, alongside other private and institutional investors from Europe, the USA and China. Proceeds will be used to progress toward a full commercial launch in Europe, conclude the UK clinical study, build a US operation and associated clinical study, and conduct further research to expand the technology's applications.